Time filter

Source Type

Orth an der Donau, Austria

Wodal W.,Vaccine R AndD | Schwendinger M.G.,Vaccine R AndD | Savidis-Dacho H.,Pharmacology R AndD | Crowe B.A.,Vaccine R AndD | And 10 more authors.

A novel avian H7N9 virus with a high case fatality rate in humans emerged in China in 2013.We evaluated the immunogenicity and protective efficacy of a candidate Vero cell culturederived whole-virus H7N9 vaccine in small animal models. Methods Antibody responses induced in immunized DBA/2J mice and guinea pigs were evaluated by hemagglutination inhibition (HI), microneutralization (MN), and neuraminidase inhibition (NAi) assays. T-helper cell responses and IgG subclass responses in mice were analyzed by ELISPOT and ELISA, respectively. Vaccine efficacy against lethal challenge with wildtype H7N9 virus was evaluated in immunized mice. H7N9-specific antibody responses induced in mice and guinea pigs were compared to those induced by a licensed whole-virus pandemic H1N1 (H1N1pdm09) vaccine. Results The whole-virus H7N9 vaccine induced dose-dependent H7N9-specific HI, MN and NAi antibodies in mice and guinea pigs. Evaluation of T-helper cell responses and IgG subclasses indicated the induction of a balanced Th1/Th2 response. Immunized mice were protected against lethal H7N9 challenge in a dose-dependent manner. H7N9 and H1N1pdm09 vaccines were similarly immunogenic. Conclusions The induction of H7N9-specific antibody and T cell responses and protection against lethal challenge suggest that the Vero cell culture-derived whole-virus vaccine would provide an effective intervention against the H7N9 virus. © 2015 Wodal et al. Source

Discover hidden collaborations